Nicolas Roussot
Overview
Explore the profile of Nicolas Roussot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roussot N, Kaderbhai C, Ghiringhelli F
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075753
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy targeting the PD-1/PD-L1 axis has revolutionized treatment, providing durable responses in a subset of patients. However, with...
2.
Bellio H, Roussot N, Bertaut A, Hervieu A, Zanetta S, Tharin Z, et al.
Future Oncol
. 2025 Feb;
21(6):699-706.
PMID: 39913183
Purpose: A phase I study of FOLFIRINOX3-bevacizumab (bFOLFIRINOX3)defined the RP2D for irinotecan at 70 mg/m² and showed promising activity. This phase II trial aimed to evaluate the efficacy of bFOLFIRINOX-3...
3.
Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):22.
PMID: 39820336
In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fully human...
4.
Fumet J, Roussot N, Bertaut A, Limagne E, Thibaudin M, Hervieu A, et al.
Future Oncol
. 2024 Nov;
20(38):3077-3085.
PMID: 39530624
Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC...
5.
Peroz M, Mananet H, Roussot N, Kaderbhai C, Derangere V, Truntzer C, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272973
Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in...
6.
Roussot N, Thibaudin M, Fumet J, Daumoine S, Hampe L, Rebe C, et al.
Front Immunol
. 2024 Aug;
15:1437961.
PMID: 39170614
A patient with a PD-L1-negative, TMB-low, co-mutated metastatic non-small cell lung cancer (NSCLC) experienced a multisite radiological progression at 3 months after initiation of chemoimmunotherapy as first-line treatment for metastatic...
7.
Hampe L, Daumoine S, Limagne E, Roussot N, Borsotti F, Vincent J, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):133.
PMID: 38753169
Background: Glioblastoma (GBM) is a primary brain tumor with a dismal prognosis, often resistant to immunotherapy and associated with immune suppression. This study aimed to assess the impact of steroids...
8.
Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, et al.
Eur J Cancer
. 2024 Mar;
202:114037.
PMID: 38554542
Background: The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select...
9.
Roussot N, Vincent J, Palmier R, Constantin G, Bengrine L, Fumet J, et al.
Front Oncol
. 2023 Dec;
13:1293670.
PMID: 38098503
Background: Advanced biliary tract cancer (BTC) has a poor prognosis. Gemcitabine with platinum chemotherapy was the standard first-line chemotherapeutic regimen until the recent addition of anti-PD-1/PD-L1 antibodies. After disease progression,...
10.
Roussot N, Fumet J, Limagne E, Thibaudin M, Hervieu A, Hennequin A, et al.
BMC Cancer
. 2023 Nov;
23(1):1080.
PMID: 37946136
Background: Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs...